PTGX Protagonist Therapeutics, InccompanySEC Filings & Insider Trading Activity 2026
Latest Protagonist Therapeutics, Inc (PTGX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on February 25, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Protagonist Therapeutics, Inc (PTGX) (SEC CIK 1377121), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Development and commercialization of pharmaceutical and biological products subject to extensive U.S. and EU regulatory oversight
- • New filings: July 2025 NDA by Johnson & Johnson for Icotyde; January 2026 NDA by Protagonist and Takeda for rusfertide for polycythemia vera
Risk Factors
- • Regulatory risk: FDA approval timing and receipt of up to $400M payments plus $75M milestone under Takeda Collaboration Agreement opt-out in 2026
- • Macroeconomic risk: exposure to geopolitical instability, high interest rates, and trade policy changes potentially impacting operations and FDA agency functioning
Management Discussion & Analysis
- • Revenue not explicitly disclosed; milestone payments: $165M (2025), $300M upfront (2024), $25M milestone (2025)
- • Net loss $130.1M in 2025 vs net income $275.2M in 2024; no margin % figures provided
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New FDA disruption risk triggered by mass federal employee layoffs since January 2025 and ongoing government shutdown starting October 2025
- • Updated macroeconomic risk from U.S. tariffs up to 100% on imported branded pharmaceuticals announced September 2025 with unclear implementation timing
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full year 2025 earnings reported February 25, 2026
- • Full results and financial details contained in the furnished press release exhibit — key figures not disclosed in this item text
Annual Reports Archive10-K
AI-powered analysis of Protagonist Therapeutics, Inc (PTGX) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Protagonist Therapeutics, Inc (PTGX) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Protagonist Therapeutics, Inc (PTGX) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $26.6M | $60.0M | $434.4M | $46.0M |
| Operating Income | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| Net Income | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| Op. Margin | -494.2% | -156.1% | 58.2% | -343.6% |
| Net Margin | -479.3% | -131.6% | 63.3% | -282.8% |
| Balance Sheet | ||||
| Total Assets | $247.9M | $358.0M | $744.7M | $668.2M |
| Equity | $215.6M | $336.7M | $675.3M | $614.7M |
| ROE | -59.1% | -23.5% | 40.8% | -21.2% |
Source: XBRL financial data from Protagonist Therapeutics, Inc (PTGX) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Feb 25, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 21, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 27, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 15, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 4, 2021 | Mar 31, 2021 | — | |
10-K | Mar 10, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 4, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 6, 2020 | Jun 30, 2020 | — |
Frequently Asked Questions
What are the latest PTGX SEC filings in 2026?
Protagonist Therapeutics, Inc (PTGX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on February 25, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did PTGX file its most recent 10-K annual report?
Protagonist Therapeutics, Inc (PTGX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view PTGX 10-Q quarterly reports?
Protagonist Therapeutics, Inc (PTGX)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every PTGX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has PTGX filed recently?
Protagonist Therapeutics, Inc (PTGX)'s most recent 8-K was filed on February 25, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find PTGX insider trading activity (Form 4)?
SignalX aggregates every PTGX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does PTGX file with the SEC?
Protagonist Therapeutics, Inc (PTGX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PTGX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Protagonist Therapeutics, Inc (PTGX).
What is PTGX's SEC CIK number?
Protagonist Therapeutics, Inc (PTGX)'s SEC CIK (Central Index Key) number is 1377121. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1377121 to look up all PTGX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find PTGX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Protagonist Therapeutics, Inc (PTGX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Protagonist Therapeutics, Inc SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 41+ filings.